Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2017

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Christelle Remy-Ziller, et al. Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article Publication

Published 12 October 2017
Categorized as -others, 2017, Publication, TG4010

Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors

20171012 PR TG4010 publications

Published 12 October 2017
Categorized as 2017, Press release, TG4010

Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors

20171002-PR-TG-Randox-final

Published 2 October 2017
Categorized as 2017, Invir.IO, Press release

Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses

20170905 Invirio PR US

Published 21 September 2017
Categorized as 2017, Invir.IO, Press release

First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

170919-Transgene-FPI-Announcement_US

Published 19 September 2017
Categorized as 2017, Press release, TG4001, TG4001

First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed

20170913 EN – CP Resultats financiers final

Published 13 September 2017
Categorized as 2017, Press release

Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)

Published 11 September 2017
Categorized as 2017, Press release, TG4010

Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress

20170907-ESMO-Metromajx-poster-EN

Published 7 September 2017
Categorized as 2017, Pexa-Vec, Press release

A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors

Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8 Download the poster here Poster Presentation

Published 7 September 2017
Categorized as -others, 2017, Pexa-Vec, Publication Tagged Oncolytic virus, Poster presentation

Transgene Announces Upcoming Investor Meetings

TNG-PR-financial-agenda-H217-EN

Published 31 August 2017
Categorized as 2017, Press release

Posts pagination

Newer posts Page 1 Page 2 … Page 5 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu